Shares of Legend Biotech LEGN rose 12.1% on Friday following an article issued by StreetInsider.com, which mentioned that the company recently received a takeover bid from an unidentified bidder. The article further claimed that LEGN hired investment banking firm Centerview Partners to assist its board of directors in reviewing this takeover offer. The article did not provide information on whether this interest could lead to a potential sale. Legend is yet to confirm these reports. Legend currently has only one marketed product in its portfolio, Carvykti, an autologous CAR-T cell therapy for multiple myeloma (MM). The therapy is marketed in partnership with pharma giant Johnson & Johnson JNJ. In April, the FDA granted label expansion to the J&J-partnered therapy to treat adult patients with MM who have received at least one prior line of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) and who are refractory to Bristol-Myers’ BMY Revlimid (lenalidomide). The therapy was initially cleared for use as a fifth-line treatment in the country in 2022. Before this label expansion, around 15% of patients initially diagnosed with MM were able to start a fifth line of therapy in the United States. With the new label, J&J and Legend Biotech expect to cater to a wider patient population. In anticipation of meeting an increased demand for the therapy post-label expansion, J&J claims that it has more than doubled its manufacturing capacity last year. The company’s pipeline is made up of investigational novel cell therapies for a variety of oncology indications, including gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, and lung cancer. Year to date, Legend Biotech’s shares have lost 9.7% compared with the industry’s 2.6% fall. Zacks Investment Research Image Source: Zacks Investment Research The takeover report also benefitted the Legend’s rival 2seventy bio TSVT, whose shares were also up 7% on Jul 12. TSVT markets Abecma, another FDA-approved CAR-T therapy that is similar to Carvykti, in partnership with Bristol Myers. Earlier this April, the FDA also granted label expansion to BMY/TSVT drug for the treatment of adults with r/r MM who have received two or more prior lines of therapy, including PI, an IMiD agent, and an anti-CD38 monoclonal antibody. Like Carvykti, Bristol Myers/2seventy’s Abecma was previously cleared for use as a fifth-line treatment in the country. While we acknowledge that both therapies are based on similar mechanisms and the new labels are expected to boost their revenue-generating potential, Carvykti’s use as an earlier line of treatment in MM patients gives it an edge over Abecma. Zacks Rank Legend Biotech currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY):Free Stock Analysis Report Johnson & Johnson (JNJ):Free Stock Analysis Report Legend Biotech Corporation Sponsored ADR (LEGN):Free Stock Analysis Report 2seventy bio, Inc. (TSVT):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...